{"id":"rt-plus-cisplatin","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Vomiting"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hair loss"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Radiation therapy (RT) uses high-energy rays to damage cancer cells' DNA, while Cisplatin is a chemotherapy drug that interferes with DNA replication, causing cancer cells to die. The combination of both treatments can be more effective than either one alone.","oneSentence":"RT plus Cisplatin works by combining radiation therapy with a chemotherapy drug to kill cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:03.243Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Testicular cancer"}]},"trialDetails":[{"nctId":"NCT02466971","phase":"PHASE3","title":"Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-10","conditions":"Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma","enrollment":450},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT06064097","phase":"PHASE2","title":"A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-25","conditions":"Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8","enrollment":50},{"nctId":"NCT05198830","phase":"PHASE2","title":"Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-15","conditions":"Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":42},{"nctId":"NCT06770582","phase":"PHASE2","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-03","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8","enrollment":160},{"nctId":"NCT05172245","phase":"PHASE1","title":"Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-09-19","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT04671667","phase":"PHASE2","title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-27","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":188},{"nctId":"NCT04533750","phase":"PHASE1","title":"Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-20","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT07195734","phase":"PHASE2","title":"Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-09","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":180},{"nctId":"NCT03952585","phase":"PHASE2, PHASE3","title":"De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-09","conditions":"Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":384},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":"Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma","enrollment":336},{"nctId":"NCT07281417","phase":"PHASE2","title":"Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-11-24","conditions":"Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8","enrollment":108},{"nctId":"NCT03775265","phase":"PHASE3","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-03","conditions":"Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8","enrollment":475},{"nctId":"NCT03811002","phase":"PHASE3","title":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-26","conditions":"Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":544},{"nctId":"NCT06323460","phase":"PHASE2","title":"Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-03-21","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT03410615","phase":"PHASE2","title":"Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-05-28","conditions":"Oropharyngeal Squamous Cell Carcinoma","enrollment":129},{"nctId":"NCT03493425","phase":"PHASE2","title":"Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-03-12","conditions":"Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","enrollment":82},{"nctId":"NCT02734537","phase":"PHASE2","title":"Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2016-11-23","conditions":"Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma","enrollment":189},{"nctId":"NCT04430699","phase":"PHASE2","title":"Cisplatin+Pembrolizumab+RT in Vulvar Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-29","conditions":"Vulvar Cancer, Vulvar Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT05941741","phase":"PHASE3","title":"IC Plus Low-dose Radiation Plus Cadonilimab in LANPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-01-10","conditions":"Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy","enrollment":380},{"nctId":"NCT02135042","phase":"PHASE2, PHASE3","title":"Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2014-04-21","conditions":"Epstein-Barr Virus Infection, Stage II Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma","enrollment":685},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT06333899","phase":"EARLY_PHASE1","title":"Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2025-08-03","conditions":"High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma","enrollment":15},{"nctId":"NCT06858735","phase":"PHASE2","title":"HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-06-10","conditions":"Advanced Intrahepatic Cholangiocarcinoma","enrollment":60},{"nctId":"NCT02402920","phase":"PHASE1","title":"Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07-22","conditions":"Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma, Neuroendocrine Neoplasm","enrollment":83},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT00707473","phase":"PHASE2","title":"Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-06-16","conditions":"Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma","enrollment":31},{"nctId":"NCT05721755","phase":"PHASE3","title":"Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-06-08","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":290},{"nctId":"NCT00797719","phase":"PHASE1, PHASE2","title":"Short Neoadjuvant Hemithoracic IMRT for MPM","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2008-10","conditions":"Malignant Pleural Mesothelioma","enrollment":104},{"nctId":"NCT05050162","phase":"PHASE2, PHASE3","title":"Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer","status":"SUSPENDED","sponsor":"NRG Oncology","startDate":"2022-02-01","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma","enrollment":1714},{"nctId":"NCT07441681","phase":"PHASE3","title":"Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin","status":"NOT_YET_RECRUITING","sponsor":"NRG Oncology","startDate":"2027-01-06","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":454},{"nctId":"NCT07039162","phase":"PHASE2","title":"Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Ming-Yu Lien","startDate":"2025-09-26","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer","enrollment":45},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT05544136","phase":"PHASE2","title":"A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-12","conditions":"Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Neoplasms","enrollment":12},{"nctId":"NCT05382338","phase":"PHASE3","title":"A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-02-20","conditions":"Childhood Medulloblastoma","enrollment":225},{"nctId":"NCT05386550","phase":"PHASE3","title":"Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-10-06","conditions":"Head and Neck Cancer","enrollment":166},{"nctId":"NCT02724579","phase":"PHASE2","title":"Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-11-17","conditions":"Medulloblastoma","enrollment":45},{"nctId":"NCT07415681","phase":"PHASE2","title":"GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries","status":"NOT_YET_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2026-03","conditions":"Gynaecologic Cancer, Cervical Cancer, Radiation Therapy","enrollment":116},{"nctId":"NCT05075980","phase":"PHASE2","title":"Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-02-16","conditions":"Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary, Hypopharyngeal Carcinoma","enrollment":174},{"nctId":"NCT03258554","phase":"PHASE2, PHASE3","title":"Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-04-03","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":196},{"nctId":"NCT02973386","phase":"PHASE3","title":"Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients","status":"COMPLETED","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2017-01-13","conditions":"Local Advanced High Risk Nasopharyngeal Carcinoma","enrollment":294},{"nctId":"NCT07371234","phase":"PHASE2","title":"Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Xiwei XU","startDate":"2025-12-15","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":22},{"nctId":"NCT07097142","phase":"PHASE3","title":"Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2026-05-11","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8","enrollment":486},{"nctId":"NCT06532279","phase":"PHASE2","title":"Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2024-12-16","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":98},{"nctId":"NCT06764355","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-07-23","conditions":"ESCC, Total Neoadjuvant Treatment, Pathological Complete Response","enrollment":50},{"nctId":"NCT03323463","phase":"PHASE2","title":"Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-10-16","conditions":"HPV-Associated Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Neck","enrollment":316},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT03937843","phase":"PHASE2","title":"Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2019-07-29","conditions":"Seminoma, Testicular Cancer","enrollment":135},{"nctId":"NCT05624996","phase":"PHASE3","title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-07-12","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":474},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT05245682","phase":"EARLY_PHASE1","title":"Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-02-17","conditions":"Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma","enrollment":10},{"nctId":"NCT06861244","phase":"PHASE2","title":"Embryonal Tumor With Multilayered Rosettes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-06","conditions":"Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos","enrollment":70},{"nctId":"NCT06676449","phase":"PHASE3","title":"TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-11-01","conditions":"Esophageal Carcinoma, Radiotherapy, Immunotherapy","enrollment":432},{"nctId":"NCT07248956","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-12-22","conditions":"Hypopharyngeal Carcinoma","enrollment":116},{"nctId":"NCT07293468","phase":"PHASE2, PHASE3","title":"Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)","status":"RECRUITING","sponsor":"Tuen Mun Hospital","startDate":"2024-04-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":106},{"nctId":"NCT01154920","phase":"PHASE2","title":"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":128},{"nctId":"NCT05340270","phase":"PHASE2","title":"PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangxi Medical University","startDate":"2022-07-15","conditions":"Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor","enrollment":150},{"nctId":"NCT06546969","phase":"PHASE1","title":"Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2024-10-29","conditions":"Biliary Tract Cancer, Cholangiocarcinoma","enrollment":15},{"nctId":"NCT02567422","phase":"PHASE1","title":"Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-17","conditions":"Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7","enrollment":43},{"nctId":"NCT02066220","phase":"PHASE2, PHASE3","title":"International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2014-06","conditions":"Brain Tumors","enrollment":360},{"nctId":"NCT06706401","phase":"PHASE3","title":"Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-02-20","conditions":"Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer","enrollment":460},{"nctId":"NCT02595879","phase":"PHASE1","title":"Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-09-18","conditions":"Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma, Advanced Cervical Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT04216290","phase":"PHASE2","title":"A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":"Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8","enrollment":95},{"nctId":"NCT03738228","phase":"PHASE1","title":"Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-07","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT03228537","phase":"PHASE1","title":"Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-16","conditions":"Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v7","enrollment":28},{"nctId":"NCT05541016","phase":"PHASE2","title":"De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-02-21","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":455},{"nctId":"NCT04169763","phase":"PHASE1","title":"Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-07","conditions":"Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8","enrollment":25},{"nctId":"NCT01495676","phase":"NA","title":"A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer","status":"TERMINATED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2011-07-06","conditions":"Infiltrating Bladder Urothelial Carcinoma","enrollment":69},{"nctId":"NCT04580771","phase":"PHASE2","title":"A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-10-14","conditions":"Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018","enrollment":22},{"nctId":"NCT04481204","phase":"PHASE2","title":"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-04-18","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma","enrollment":105},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT06560697","phase":"NA","title":"Cervical Boost by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma","status":"RECRUITING","sponsor":"National Institute of Cancerología","startDate":"2024-05-15","conditions":"Uterine Cervical Neoplasm","enrollment":84},{"nctId":"NCT06056310","phase":"PHASE1","title":"Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-01-18","conditions":"Head and Neck Cancer","enrollment":18},{"nctId":"NCT01326468","phase":"NA","title":"Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-12-08","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT04722523","phase":"PHASE1","title":"A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-01-20","conditions":"Head and Neck Cancer, Head Cancer, Head Cancer Neck","enrollment":40},{"nctId":"NCT02788461","phase":"NA","title":"Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2016-05","conditions":"Non-Small Cell Lung Cancer","enrollment":78},{"nctId":"NCT06865339","phase":"PHASE2","title":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Nitin Ohri","startDate":"2025-08-07","conditions":"NSCLC, Locally Advanced","enrollment":76},{"nctId":"NCT07153952","phase":"PHASE1, PHASE2","title":"RT for Adenocarcinoma/Adenosquamous Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-01-01","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Radiotherapy","enrollment":60},{"nctId":"NCT03070366","phase":"PHASE2","title":"Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2015-09-21","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":78},{"nctId":"NCT03340896","phase":"PHASE3","title":"Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2015-06-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":256},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma","enrollment":29},{"nctId":"NCT02363400","phase":"PHASE3","title":"A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA","status":"TERMINATED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2014-12-14","conditions":"Nasopharyngeal Carcinoma","enrollment":10},{"nctId":"NCT06543576","phase":"PHASE1, PHASE2","title":"External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-07-29","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma","enrollment":35},{"nctId":"NCT07121595","phase":"PHASE2","title":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-07-17","conditions":"Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8","enrollment":50},{"nctId":"NCT04900623","phase":"PHASE2","title":"Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study","status":"RECRUITING","sponsor":"Jonathan Schoenfeld, MD, MPH","startDate":"2021-07-02","conditions":"HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage","enrollment":145},{"nctId":"NCT06734702","phase":"PHASE3","title":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy","enrollment":497},{"nctId":"NCT06545747","phase":"PHASE3","title":"Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-01","conditions":"Non-small Cell Lung Cancer","enrollment":490},{"nctId":"NCT07046221","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Esophagus Cancer","enrollment":60},{"nctId":"NCT04833257","phase":"PHASE2","title":"Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-04-14","conditions":"Nasopharyngeal Carcinoma","enrollment":63},{"nctId":"NCT05388773","phase":"PHASE2","title":"Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer","status":"RECRUITING","sponsor":"Heath Skinner","startDate":"2022-07-20","conditions":"Oropharynx Cancer","enrollment":150},{"nctId":"NCT00392327","phase":"PHASE3","title":"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2007-05-23","conditions":"Anaplastic Medulloblastoma, Medulloblastoma","enrollment":379},{"nctId":"NCT06009861","phase":"PHASE2","title":"Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University Hospital of Stomatology","startDate":"2023-06-27","conditions":"Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma","enrollment":110},{"nctId":"NCT03612791","phase":"PHASE2","title":"Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-08-13","conditions":"Locally Advanced Cervical Cancer","enrollment":189},{"nctId":"NCT06848439","phase":"PHASE2","title":"Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-06-15","conditions":"Mouth Neoplasms, Neoadjuvant Therapy, Immunotherapy","enrollment":26},{"nctId":"NCT00324415","phase":"PHASE2","title":"Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2006-09","conditions":"Anal Cancer","enrollment":45},{"nctId":"NCT01101451","phase":"PHASE3","title":"Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery","status":"COMPLETED","sponsor":"GOG Foundation","startDate":"2010-04-12","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified","enrollment":340},{"nctId":"NCT03387774","phase":"PHASE3","title":"Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2018-01-30","conditions":"Oral Mucositis (Ulcerative) Due to Radiation","enrollment":179},{"nctId":"NCT04456322","phase":"PHASE3","title":"Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-08-17","conditions":"Nasopharyngeal Carcinoma","enrollment":381}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":510,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cisplatin"],"phase":"phase_3","status":"active","brandName":"RT plus Cisplatin","genericName":"RT plus Cisplatin","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RT plus Cisplatin works by combining radiation therapy with a chemotherapy drug to kill cancer cells. Used for Non-small cell lung cancer, Ovarian cancer, Testicular cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}